Roche, Molecular Partners enter alliance to develop new treatments Roche and Molecular Partners announced that they have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partnersí DARPin biologics conjugated to toxic agents developed at Roche for the treatment of cancer. Under the terms of the agreement, Roche has rights to develop and commercialize several DARPin-based products. Molecular Partners is entitled to receive upfront and initiation payments up to CHF55M. Furthermore, Molecular Partners will receive research funding and can earn more than CHF1B if all development and sales milestones are met for all potential products. In addition Molecular Partners will receive tiered royalties on any future product sales into the double-digit percentage range.